Vaccinex Announces $6.6 Million Private Placement
January 27, 2022 16:15 ET
|
Vaccinex, Inc.
Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) --...
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
January 26, 2022 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
November 09, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizumab déclenche un paiement de 50M$ d'AstraZeneca
October 23, 2020 01:00 ET
|
INNATE PHARMA
Ce paiement d’étape renforce la position de trésorerie d’Innate INTERLINK-1 est la première étude de Phase 3 étudiant une approche d’immunothérapie chez des patients présentant un cancer de la tête...
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
October 23, 2020 01:00 ET
|
INNATE PHARMA
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...
First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
October 23, 2020 01:00 ET
|
INNATE PHARMA
Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy...